Trial Profile

A single-arm, open-label, single-center study of GC027 injection in relapse and refractory T-ALL or relapse and refractory T-LBL

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 027 (Primary) ; Cyclophosphamide; Fludarabine
Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Gracell Biotechnology

Most Recent Events

08 Sep 2023 As per ISRCTN: Current Controlled Trials record. Recruitment End Date: 31/12/2024
08 Sep 2023 Planned End Date changed from 1 May 2022 to 31 Dec 2025.
03 May 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com